NCT01341834 2018-04-24
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
National Cancer Centre, Singapore
Phase 1 Unknown
Clinical Trials
7 trialsNCT01451268 2018-03-20
PANOBEST
Johann Wolfgang Goethe University Hospital
Phase 1/2 Unknown
NCT02145715 2015-06-26
MUKsix
University of Leeds
Phase 1/2 Unknown
NCT01298934 2015-03-06
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT01884428 2014-01-29
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 1 Unknown
NCT01175109 2012-12-27
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Phase 1 Unknown
NCT01159418 2011-09-13
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown